Urinary Post-Translationally Modified Fetuin-A (uPTM-FetA) in Chronic Kidney Disease Patients with and without Diabetic Kidney Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Cohort
2.2. Clinical Assessment
2.3. Post-Translationally Modified Fetuin-A Fragments in Urine (uPTM-FetA) Measurement
2.4. Statistical Analysis
3. Results
3.1. Clinical Characteristics and uPTM-FetA Measurement in the Study Cohort
3.2. Clinical Correlates of uPTM-FetA in CKD Patients
3.3. ROC Analyses of uPTM-FetA
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the global burden of disease study 2017. Lancet 2020, 395, 709–733. [Google Scholar] [CrossRef] [PubMed]
- Cockwell, P.; Fisher, L.A. The global burden of chronic kidney disease. Lancet 2020, 395, 662–664. [Google Scholar] [CrossRef] [PubMed]
- Noels, H.; Jankowski, J. Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: Introduction to a Compendium. Circ. Res. 2023, 132, 899–901. [Google Scholar] [CrossRef] [PubMed]
- de Boer, I.H.; Khunti, K.; Sadusky, T.; Tuttle, K.R.; Neumiller, J.J.; Rhee, C.M.; Rosas, S.E.; Rossing, P.; Bakris, G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022, 45, 3075–3090. [Google Scholar] [CrossRef] [PubMed]
- Wittmann, I.; Molnar, G.A.; Degrell, P.; Wagner, Z.; Tamasko, M.; Laczy, B.; Brasnyo, P.; Wagner, L.; Nagy, J. Prevention and treatment of diabetic nephropathy. Diabetes Res. Clin. Pract. 2005, 68 (Suppl. S1), S36–S42. [Google Scholar] [CrossRef] [PubMed]
- Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [Google Scholar] [CrossRef] [PubMed]
- Fiorentino, M.; Bolignano, D.; Tesar, V.; Pisano, A.; Biesen, W.V.; Tripepi, G.; D’Arrigo, G.; Gesualdo, L.; ERA-EDTA Immunonephrology Working Group. Renal biopsy in patients with diabetes: A pooled meta-analysis of 48 studies. Nephrol. Dial. Transplant. 2017, 32, 97–110. [Google Scholar] [CrossRef] [PubMed]
- Bolignano, D.; Zoccali, C. Non-proteinuric rather than proteinuric renal diseases are the leading cause of end-stage kidney disease. Nephrol. Dial. Transplant. 2017, 32, ii194–ii199. [Google Scholar] [CrossRef] [PubMed]
- Chuang, G.T.; Kremer, D.; Huang, C.H.; Alkaff, F.F.; Lin, C.H.; Tseng, T.L.; Laverman, G.D.; Bakker, S.J.L.; Chuang, L.M. Urinary fetuin-a fragments predict progressive egfr decline in two independent type 2 diabetes cohorts of different ethnicities. Am. J. Nephrol. 2024, 55, 106–114. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.C.; Bowman, B.H.; Yang, F.M. Human alpha 2-hs-glycoprotein: The a and b chains with a connecting sequence are encoded by a single mrna transcript. Proc. Natl. Acad. Sci. USA 1987, 84, 4403–4407. [Google Scholar] [CrossRef] [PubMed]
- Magalhaes, P.; Zurbig, P.; Mischak, H.; Schleicher, E. Urinary fetuin-a peptides as a new marker for impaired kidney function in patients with type 2 diabetes. Clin. Kidney J. 2021, 14, 269–276. [Google Scholar] [CrossRef] [PubMed]
- Chekol Abebe, E.; Tilahun Muche, Z.; Behaile, T.M.A.; Mengie Ayele, T.; Mekonnen Agidew, M.; Teshome Azezew, M.; Abebe Zewde, E.; Asmamaw Dejenie, T.; Asmamaw Mengstie, M. The structure, biosynthesis, and biological roles of fetuin-a: A review. Front. Cell Dev. Biol. 2022, 10, 945287. [Google Scholar] [CrossRef] [PubMed]
- Trepanowski, J.F.; Mey, J.; Varady, K.A. Fetuin-a: A novel link between obesity and related complications. Int. J. Obes. 2015, 39, 734–741. [Google Scholar] [CrossRef] [PubMed]
- Inoue, K.; Wada, J.; Eguchi, J.; Nakatsuka, A.; Teshigawara, S.; Murakami, K.; Ogawa, D.; Terami, T.; Katayama, A.; Tone, A.; et al. Urinary fetuin-a is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray. PLoS ONE 2013, 8, e77118. [Google Scholar] [CrossRef] [PubMed]
- Zhou, H.; Pisitkun, T.; Aponte, A.; Yuen, P.S.; Hoffert, J.D.; Yasuda, H.; Hu, X.; Chawla, L.; Shen, R.F.; Knepper, M.A.; et al. Exosomal fetuin-a identified by proteomics: A novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006, 70, 1847–1857. [Google Scholar] [CrossRef] [PubMed]
- Piazzon, N.; Bernet, F.; Guihard, L.; Leonhard, W.N.; Urfer, S.; Firsov, D.; Chehade, H.; Vogt, B.; Piergiovanni, S.; Peters, D.J.; et al. Urine fetuin-a is a biomarker of autosomal dominant polycystic kidney disease progression. J. Transl. Med. 2015, 13, 103. [Google Scholar] [CrossRef] [PubMed]
All CKD n: 47 | Non-DKD n: 13 | DKD n: 34 | p | |
---|---|---|---|---|
Age (years) | 71.6 ± 10 | 72 ± 8.8 | 70.9 ± 9.5 | 0.32 |
Male sex (%) | 63.8 | 61.5 | 64.7 | 0.77 |
Anti-hypertensive therapy | ||||
-ACEi/ARBs (%) | 85.1 | 84.6 | 90.6 | 0.22 |
-Beta-blockers (%) | 44.6 | 38.4 | 47 | 0.56 |
-CCBs (%) | 44.6 | 38.4 | 47 | 0.56 |
-Aldosterone antagonists (%) | 6.4 | 7.6 | 5.9 | 0.68 |
-Furosemide (%) | 80.8 | 76.9 | 82.3 | 0.35 |
SGLT-2 inhibitors (%) | 42.5 | 23 | 50 | 0.03 |
Statins (%) | 82.9 | 46.1 | 97 | 0.01 |
BMI (Kg/m2) | 28.7 ± 5.3 | 25.6 ± 5.1 | 28.5 ± 5.1 | 0.01 |
Systolic BP (mmHg) | 130 ± 18.2 | 133.6 ± 18.8 | 125.4 ± 15.6 | 0.05 |
Diastolic BP (mmHg) | 72.5 ± 9.3 | 71 ± 8.2 | 73.2 ± 11.8 | 0.37 |
CKD-Epi eGFR (mL/min/1.73 m2) | 40.1 ± 16.5 | 38.5 ± 12.6 | 43.3 ± 9.8 | 0.05 |
Serum Creatinine (mg/dL) | 1.8 ± 0.66 | 1.95 ± 0.77 | 1.68 ± 0.45 | 0.05 |
Urea (mg/dL) | 78.9 ± 27.1 | 83.8 ± 29.6 | 77.8 ± 19.6 | 0.05 |
Albumin (g/dL) | 4.28 ± 0.44 | 4.31 ± 0.65 | 4.19 ± 0.28 | 0.68 |
Serum Sodium (mmol/L) | 140.2 ± 3.6 | 138.7 ± 38 | 141.2 ± 2.3 | 0.38 |
Serum Potassium (mmol/L) | 4.25 ± 0.31 | 4.54 ± 0.61 | 4.13 ± 0.35 | 0.55 |
Serum Calcium (mg/dL) | 9.02 ± 0.13 | 9 ± 0.81 | 9.12 ± 0.39 | 0.88 |
Serum Phosphate (mg/dL) | 3.8 ± 0.83 | 3.82 ± 0.54 | 3.76 ± 0.36 | 0.54 |
Red blood cells (n × 106) | 4.5 ± 0.9 | 4.45 ± 0.9 | 4.69 ± 0.6 | 0.88 |
Hemoglobin (g/dL) | 12.5 ± 0.7 | 12.4 ± 0.5 | 12.5 ± 1.6 | 0.26 |
Platelets (n × 103) | 228.8 ± 54 | 235 ± 65.7 | 200.6 ± 70.1 | 0.05 |
Total Cholesterol (mg/dL) | 146.3 ± 38.6 | 139.5 ± 16.2 | 172.6 ± 18.2 | 0.04 |
LDL Cholesterol (mg/dL) | 74 ± 18 | 70 ± 21.7 | 75 ± 18.7 | 0.11 |
Triglycerides (mg/dL) | 126[81–173.2] | 140.1 [77.1–180] | 119 [3.2–99.8] | 0.61 |
iPTH (pg/mL) | 84.3 [42.7–165.3] | 103 [44.8–201.4] | 79 [51.7–133] | 0.08 |
Uric Acid (mg/dL) | 5.2 ± 1.2 | 5.32 ± 1.41 | 5.1 ± 1.64 | 0.90 |
Creatinuria (mg/dL) | 11.5 [9.4–16] | 11.1 [3.1–13.2] | 11.4 [9.4–17.2] | 0.37 |
Proteinuria (g/24 h/1.73 m2) | 0.266 [0.124–0.667] | 0.14 [0.168–0.312] | 0.381 [0.080–0.751] | 0.04 |
Urine sodium (mg/24 h) | 150.7 ± 58.8 | 153.3 ± 59.9 | 149.6 ± 40.9 | 0.56 |
Urine potassium (mg/24 h) | 49.2 ± 11.3 | 50.2 ± 9.1 | 49.1 ± 11.8 | 0.77 |
uPTM-FetA (ng/mL) | 29.68 [2.50–55.16] | 1.66 [0.09–4.19] | 13.9 [0.01–45.02] | 0.01 |
R | p | |
---|---|---|
BMI | −0.323 | p = 0.02 |
Vitamin-D | −0.517 | p = 0.005 |
Proteinuria | 0.312 | p = 0.04 |
Gamma-GT | 0.775 | p = 0.02 |
Urinary Potassium | 0.382 | p = 0.04 |
β | p | |
BMI | −0.334 | p = 0.04 |
Proteinuria | 0.442 | p = 0.02 |
Vitamin-D | 0.097 | p = 0.35 |
Gamma-GT | 0.123 | p = 0.45 |
Urinary Potassium | −0.012 | p = 0.63 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Musolino, M.; Greco, M.; D’Agostino, M.; Tripodi, L.; Misiti, R.; Dragone, F.; Cianfrone, P.; Zicarelli, M.; Foti, D.P.; Andreucci, M.; et al. Urinary Post-Translationally Modified Fetuin-A (uPTM-FetA) in Chronic Kidney Disease Patients with and without Diabetic Kidney Disease. Medicina 2024, 60, 363. https://doi.org/10.3390/medicina60030363
Musolino M, Greco M, D’Agostino M, Tripodi L, Misiti R, Dragone F, Cianfrone P, Zicarelli M, Foti DP, Andreucci M, et al. Urinary Post-Translationally Modified Fetuin-A (uPTM-FetA) in Chronic Kidney Disease Patients with and without Diabetic Kidney Disease. Medicina. 2024; 60(3):363. https://doi.org/10.3390/medicina60030363
Chicago/Turabian StyleMusolino, Michela, Marta Greco, Mario D’Agostino, Loredana Tripodi, Roberta Misiti, Francesco Dragone, Paola Cianfrone, Mariateresa Zicarelli, Daniela Patrizia Foti, Michele Andreucci, and et al. 2024. "Urinary Post-Translationally Modified Fetuin-A (uPTM-FetA) in Chronic Kidney Disease Patients with and without Diabetic Kidney Disease" Medicina 60, no. 3: 363. https://doi.org/10.3390/medicina60030363